Gil'ad N Cohen1, Karen Episcopia1, Seng-Boh Lim1, Thomas J LoSasso1, Mark J Rivard2, Amandeep S Taggar3, Neil K Taunk3, Abraham J Wu3, Antonio L Damato4. 1. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: damatoa@mskcc.org.
Abstract
PURPOSE: To present the clinical commissioning of a novel 103Pd directional brachytherapy device (CivaSheet) for intraoperative radiation therapy. METHODS AND MATERIALS: Clinical commissioning for the CivaSheet consisted of establishing: (1) source strength calibration capabilities, (2) experimental verification of TG-43 dosimetry parameters, (3) treatment planning system validation, and (4) departmental practice for dose specification and source ordering. Experimental verification was performed in water with radiochromic film calibrated with a 37 kVp X-ray beam. Percentage difference ([measurements - calculation]/calculation) and distance to agreement (difference between film-to-source distance and distance that minimized the percentage difference) were calculated. Nomogram values (in U/100 Gy) for all configurations (up to 20 × 20 sources) were calculated for source ordering. Clinical commissioning was used on patients enrolled in an ongoing Institutional Review Board-approved protocol. RESULTS: A source calibration procedure was established, and the treatment planning system was commissioned within standard clinical uncertainties. Percentage dose differences (distances to agreement) between measured and calculated doses were 8.6% (-0.12 mm), 0.6% (-0.01 mm), -6.4% (0.22 mm), and -10.0% (0.44 mm) at depths of 2.3, 5.1, 8.0, and 11.1 mm, respectively. All differences were within the experimental uncertainties. Nomogram values depended on sheet size and spatial extent. A value of 2.4U/100 Gy per CivaDot was found to satisfy most cases, ranging from 2.3 to 3.3U/100 Gy. Nomogram results depended on elongation of the treatment area with a higher variation observed for smaller treatment areas. Postimplantation dose evaluation was feasible. CONCLUSIONS: Commissioning and clinical deployment of CivaSheet was feasible using BrachyVision for postoperative dose evaluation. Experimental verification confirmed that the available TG-43 dosimetry parameters are accurate for clinical use.
PURPOSE: To present the clinical commissioning of a novel 103Pd directional brachytherapy device (CivaSheet) for intraoperative radiation therapy. METHODS AND MATERIALS: Clinical commissioning for the CivaSheet consisted of establishing: (1) source strength calibration capabilities, (2) experimental verification of TG-43 dosimetry parameters, (3) treatment planning system validation, and (4) departmental practice for dose specification and source ordering. Experimental verification was performed in water with radiochromic film calibrated with a 37 kVp X-ray beam. Percentage difference ([measurements - calculation]/calculation) and distance to agreement (difference between film-to-source distance and distance that minimized the percentage difference) were calculated. Nomogram values (in U/100 Gy) for all configurations (up to 20 × 20 sources) were calculated for source ordering. Clinical commissioning was used on patients enrolled in an ongoing Institutional Review Board-approved protocol. RESULTS: A source calibration procedure was established, and the treatment planning system was commissioned within standard clinical uncertainties. Percentage dose differences (distances to agreement) between measured and calculated doses were 8.6% (-0.12 mm), 0.6% (-0.01 mm), -6.4% (0.22 mm), and -10.0% (0.44 mm) at depths of 2.3, 5.1, 8.0, and 11.1 mm, respectively. All differences were within the experimental uncertainties. Nomogram values depended on sheet size and spatial extent. A value of 2.4U/100 Gy per CivaDot was found to satisfy most cases, ranging from 2.3 to 3.3U/100 Gy. Nomogram results depended on elongation of the treatment area with a higher variation observed for smaller treatment areas. Postimplantation dose evaluation was feasible. CONCLUSIONS: Commissioning and clinical deployment of CivaSheet was feasible using BrachyVision for postoperative dose evaluation. Experimental verification confirmed that the available TG-43 dosimetry parameters are accurate for clinical use.
Authors: A Sam Beddar; Sunil Krishnan; Tina M Briere; Xiaochun Wang; Marc E Delclos; Matthew T Ballo; Prajnan Das; Spencer Gould; John L Horton; Christopher H Crane Journal: Radiother Oncol Date: 2006-01-10 Impact factor: 6.280
Authors: Stephanie Terezakis; Lisa Morikawa; Abraham Wu; Zhigang Zhang; Weiji Shi; Martin R Weiser; Philip B Paty; Jose Guillem; Larissa Temple; Garrett M Nash; Michael J Zelefsky; Karyn A Goodman Journal: Ann Surg Oncol Date: 2015-01-29 Impact factor: 5.344
Authors: Olga Ivanov; Adam Dickler; Bennett Y F Lum; James V Pellicane; Darius S Francescatti Journal: Ann Surg Oncol Date: 2010-08-25 Impact factor: 5.344
Authors: Mauricio Cambeiro; José Javier Aristu; Marta Moreno Jimenez; Leire Arbea; Luis Ramos; Mikel San Julian; Ignacio Azinovic; Felipe A Calvo; Rafael Martínez-Monge Journal: Brachytherapy Date: 2014-10-22 Impact factor: 2.362
Authors: K M Alektiar; M J Zelefsky; P B Paty; J Guillem; L B Saltz; A M Cohen; B D Minsky Journal: Int J Radiat Oncol Biol Phys Date: 2000-08-01 Impact factor: 7.038
Authors: Luc Beaulieu; Asa Carlsson Tedgren; Jean-Francois Carrier; Stephen D Davis; Firas Mourtada; Mark J Rivard; Rowan M Thomson; Frank Verhaegen; Todd A Wareing; Jeffrey F Williamson Journal: Med Phys Date: 2012-10 Impact factor: 4.071
Authors: Michael R Folkert; Mark H Bilsky; Gil'ad N Cohen; Laszlo Voros; Jung Hun Oh; Marco Zaider; Ilya Laufer; Yoshiya Yamada Journal: Brachytherapy Date: 2014-12-04 Impact factor: 2.362
Authors: L B Harrison; B D Minsky; W E Enker; B Mychalczak; J Guillem; P B Paty; L Anderson; C White; A M Cohen Journal: Int J Radiat Oncol Biol Phys Date: 1998-09-01 Impact factor: 7.038
Authors: Christopher Fleming; Andreas Rimner; Gil'ad N Cohen; Kaitlin M Woo; Zhigang Zhang; Kenneth E Rosenzweig; Kaled M Alektiar; Michael J Zelefsky; Manjit S Bains; Abraham J Wu Journal: Brachytherapy Date: 2016-01-26 Impact factor: 2.362
Authors: Serguei A Castaneda; Marian Khalili; Jacqueline Emrich; Veronica M Zoghbi; Michael S Weingarten; Mark J Rivard; Wilbur B Bowne; Jaganmohan Poli Journal: Adv Radiat Oncol Date: 2019-07-26